Contributions
Abstract: EP1734
Type: Poster Sessions
Abstract Category: Therapy - Others
Introduction: The use of drugs that modify the immune system by patients with multiple sclerosis (MS) is rapidly increasing and so is the risk of getting infections, some of them severe. The hepatitis B vaccine (HB) induces protective concentrations of HB surface antibodies (anti-HBs) in more than 90·% of healthy adults under the age of 40. MS patients risk losing these protective titers when treated with immunomodulators.
Objective: To study whether patients undergoing immunomodulator treatment for MS maintain the protective titers of anti-HBs equal to or greater than 10 mIU/ml.
Method: A unicentric, national, cross-sectional and retrospective observational study. Inclusion criteria: patients with RRMS>18 years with positive vaccine response to HB and at least 6 months of treatment with natalizumab (NTZ), alemtuzumab (ALM), fingolimod (FIN), teriflunomide or dimethyl fumarate (DMF) after vaccination. Main variable: percentage of patients who maintain positive vaccine response after at least 6 months after the start of treatment. Secondary variables: demographic and clinical considerations of the vaccine schedule and MS drugs. Statistical analysis: descriptive. The study was approved by the hospital ethics committee and all patients signed the informed consent.
Results: Fifteen patients were included: 73% women, average age 36 +/- 7.8 years; time since diagnosis: 4 years (1-15 years); EDSS at the inclusion: 2.7 +/- 1.5. Treatment at the inclusion: DMF 46.7%, ALM 20%, FIN 20%, NTZ 13.3%. Previous treatments had been used in 40% of patients, requiring an average of 2 treatments (1-7 treatments).
53% had been previously vaccinated and the anti-HBs titers were positive before starting treatment. The other 47% had anti-HBs titers below 10 mIU/ml and they required vaccination, receiving at least 1 dose before starting treatment.
All patients maintained anti-HBs titers of >=10mIU/ml after an average of 10 months (6-37 months) of immunomodulator treatment.
Conclusions: MS patients maintain sero-conversion levels after HB vaccination in spite of immunomodulator treatment.
Disclosure: Authors have not conflict of interest and have not received funding for this study.
Abstract: EP1734
Type: Poster Sessions
Abstract Category: Therapy - Others
Introduction: The use of drugs that modify the immune system by patients with multiple sclerosis (MS) is rapidly increasing and so is the risk of getting infections, some of them severe. The hepatitis B vaccine (HB) induces protective concentrations of HB surface antibodies (anti-HBs) in more than 90·% of healthy adults under the age of 40. MS patients risk losing these protective titers when treated with immunomodulators.
Objective: To study whether patients undergoing immunomodulator treatment for MS maintain the protective titers of anti-HBs equal to or greater than 10 mIU/ml.
Method: A unicentric, national, cross-sectional and retrospective observational study. Inclusion criteria: patients with RRMS>18 years with positive vaccine response to HB and at least 6 months of treatment with natalizumab (NTZ), alemtuzumab (ALM), fingolimod (FIN), teriflunomide or dimethyl fumarate (DMF) after vaccination. Main variable: percentage of patients who maintain positive vaccine response after at least 6 months after the start of treatment. Secondary variables: demographic and clinical considerations of the vaccine schedule and MS drugs. Statistical analysis: descriptive. The study was approved by the hospital ethics committee and all patients signed the informed consent.
Results: Fifteen patients were included: 73% women, average age 36 +/- 7.8 years; time since diagnosis: 4 years (1-15 years); EDSS at the inclusion: 2.7 +/- 1.5. Treatment at the inclusion: DMF 46.7%, ALM 20%, FIN 20%, NTZ 13.3%. Previous treatments had been used in 40% of patients, requiring an average of 2 treatments (1-7 treatments).
53% had been previously vaccinated and the anti-HBs titers were positive before starting treatment. The other 47% had anti-HBs titers below 10 mIU/ml and they required vaccination, receiving at least 1 dose before starting treatment.
All patients maintained anti-HBs titers of >=10mIU/ml after an average of 10 months (6-37 months) of immunomodulator treatment.
Conclusions: MS patients maintain sero-conversion levels after HB vaccination in spite of immunomodulator treatment.
Disclosure: Authors have not conflict of interest and have not received funding for this study.